Drugmaker Refuses FDA's Request to Pull Gene Therapy Tied to Patient Deaths

(MedPage Today) — Sarepta Therapeutics will continue to ship its gene therapy delandistrogene moxeparvovec (Elevidys) to ambulant patients with Duchenne muscular dystrophy, despite the FDA’s request to halt distribution, the company stated late…

Source link : https://www.medpagetoday.com/neurology/generalneurology/116598

Author :

Publish date : 2025-07-21 16:57:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

Drugmaker Refuses FDA’s Request to Pull Gene Therapy Tied to Patient Deaths

Four-day working week may boost our health and performance at work

FDA Names Former Pharma Executive to Oversee U.S. Drug Program

Related Posts

Study Cites Urgent Care Clinics for Inappropriate Prescribing

Urgent Care Linked to High Prescribing Rates

Memory Cafes Ignite Laughter and Connection for Dementia Patients and Caregivers

Advanced Cancer Patients on Private Insurance Face High Out-of-Pocket Costs

Fetal Isotretinoin Exposure Persists Despite REMS

Gene Therapy May Hold Better Outcomes for Congenital Deafness Than Cochlear Implant

Study Cites Urgent Care Clinics for Inappropriate Prescribing

Urgent Care Linked to High Prescribing Rates

Memory Cafes Ignite Laughter and Connection for Dementia Patients and Caregivers

Advanced Cancer Patients on Private Insurance Face High Out-of-Pocket Costs

Fetal Isotretinoin Exposure Persists Despite REMS

Gene Therapy May Hold Better Outcomes for Congenital Deafness Than Cochlear Implant

NHS strike days plan puts patients at risk, says BMA

High Oxygen During Cord Clamping Helps Extremely Preterm Infants

Categories

Archives